TISIDB

Summary
Symbol	EDEM3
Name	ER degradation enhancer, mannosidase alpha-like 3
Aliases	C1orf22; chromosome 1 open reading frame 22; ER degradation-enhancing -mannosidase-like protein 3; ER degrad ......
Chromosomal Location	1q25
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Endoplasmic reticulum lumen
Domain	PF01532 Glycosyl hydrolase family 47 PF02225 PA domain
Function	Involved in endoplasmic reticulum-associated degradation (ERAD). Accelerates the glycoprotein ERAD by proteasomes, by catalyzing mannose trimming from Man8GlcNAc2 to Man7GlcNAc2 in the N-glycans. Seems to have alpha 1,2-mannosidase activity (By similarity).

> Gene Ontology [ TOP ]
Biological Process	GO:0006486 protein glycosylation GO:0006487 protein N-linked glycosylation GO:0006491 N-glycan processing GO:0006516 glycoprotein catabolic process GO:0006517 protein deglycosylation GO:0006986 response to unfolded protein GO:0009100 glycoprotein metabolic process GO:0009101 glycoprotein biosynthetic process GO:0009311 oligosaccharide metabolic process GO:0010498 proteasomal protein catabolic process GO:0030433 ER-associated ubiquitin-dependent protein catabolic process GO:0030968 endoplasmic reticulum unfolded protein response GO:0034620 cellular response to unfolded protein GO:0034976 response to endoplasmic reticulum stress GO:0035966 response to topologically incorrect protein GO:0035967 cellular response to topologically incorrect protein GO:0035977 protein deglycosylation involved in glycoprotein catabolic process GO:0036503 ERAD pathway GO:0036507 protein demannosylation GO:0036508 protein alpha-1,2-demannosylation GO:0043161 proteasome-mediated ubiquitin-dependent protein catabolic process GO:0043413 macromolecule glycosylation GO:0044723 single-organism carbohydrate metabolic process GO:0070085 glycosylation GO:0097466 glycoprotein ERAD pathway GO:1901136 carbohydrate derivative catabolic process GO:1904380 endoplasmic reticulum mannose trimming GO:1904382 mannose trimming involved in glycoprotein ERAD pathway GO:1904587 response to glycoprotein
Molecular Function	GO:0004553 hydrolase activity, hydrolyzing O-glycosyl compounds GO:0004559 alpha-mannosidase activity GO:0004569 glycoprotein endo-alpha-1,2-mannosidase activity GO:0004571 mannosyl-oligosaccharide 1,2-alpha-mannosidase activity GO:0015923 mannosidase activity GO:0015924 mannosyl-oligosaccharide mannosidase activity GO:0016798 hydrolase activity, acting on glycosyl bonds
Cellular Component	GO:0005788 endoplasmic reticulum lumen GO:0044322 endoplasmic reticulum quality control compartment

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa04141 Protein processing in endoplasmic reticulum
Reactome	R-HSA-446203: Asparagine N-linked glycosylation R-HSA-901042: Calnexin/calreticulin cycle R-HSA-901032: ER Quality Control Compartment (ERQC) R-HSA-392499: Metabolism of proteins R-HSA-532668: N-glycan trimming in the ER and Calnexin/Calreticulin cycle R-HSA-597592: Post-translational protein modification

Summary
Symbol	EDEM3
Name	ER degradation enhancer, mannosidase alpha-like 3
Aliases	C1orf22; chromosome 1 open reading frame 22; ER degradation-enhancing -mannosidase-like protein 3; ER degrad ......
Chromosomal Location	1q25
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between EDEM3 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	EDEM3
Name	ER degradation enhancer, mannosidase alpha-like 3
Aliases	C1orf22; chromosome 1 open reading frame 22; ER degradation-enhancing -mannosidase-like protein 3; ER degrad ......
Chromosomal Location	1q25
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of EDEM3 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	logFC: 1.35; FDR: 0.000150	Sensitive to T cell-mediated killing
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	EDEM3
Name	ER degradation enhancer, mannosidase alpha-like 3
Aliases	C1orf22; chromosome 1 open reading frame 22; ER degradation-enhancing -mannosidase-like protein 3; ER degrad ......
Chromosomal Location	1q25
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of EDEM3 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	-0.422	0.135
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	-0.446	0.782
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	-0.402	0.729
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0.063	0.843
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	-0.061	0.975
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0.224	0.932
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0.237	0.576
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	-0.032	0.986
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0.545	0.786
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	0.436	0.707
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	0.932	0.582
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	0.037	0.509

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of EDEM3 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	3.7	2.7	1	1
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	3.7	3.4	0.3	1
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	4.8	0	4.8	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	7.7	0	7.7	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	11.1	0	11.1	0.36
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	25	0	25	0.364
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	5.3	3.7	1.6	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	9.1	7.7	1.4	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	9.1	0	9.1	0.458
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	16.7	0	16.7	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	EDEM3
Name	ER degradation enhancer, mannosidase alpha-like 3
Aliases	C1orf22; chromosome 1 open reading frame 22; ER degradation-enhancing -mannosidase-like protein 3; ER degrad ......
Chromosomal Location	1q25
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of EDEM3. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	EDEM3
Name	ER degradation enhancer, mannosidase alpha-like 3
Aliases	C1orf22; chromosome 1 open reading frame 22; ER degradation-enhancing -mannosidase-like protein 3; ER degrad ......
Chromosomal Location	1q25
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of EDEM3. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by EDEM3. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	EDEM3
Name	ER degradation enhancer, mannosidase alpha-like 3
Aliases	C1orf22; chromosome 1 open reading frame 22; ER degradation-enhancing -mannosidase-like protein 3; ER degrad ......
Chromosomal Location	1q25
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of EDEM3. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	EDEM3
Name	ER degradation enhancer, mannosidase alpha-like 3
Aliases	C1orf22; chromosome 1 open reading frame 22; ER degradation-enhancing -mannosidase-like protein 3; ER degrad ......
Chromosomal Location	1q25
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of EDEM3 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	EDEM3
Name	ER degradation enhancer, mannosidase alpha-like 3
Aliases	C1orf22; chromosome 1 open reading frame 22; ER degradation-enhancing -mannosidase-like protein 3; ER degrad ......
Chromosomal Location	1q25
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between EDEM3 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	EDEM3
Name	ER degradation enhancer, mannosidase alpha-like 3
Aliases	C1orf22; chromosome 1 open reading frame 22; ER degradation-enhancing -mannosidase-like protein 3; ER degrad ......
Chromosomal Location	1q25
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting EDEM3 collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse EDEM3